Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
Aarti, Adcirca, Aetna, agonist, Agri, AIA, AMP, AOCL, arbitration, arose, Arzneimittel, ASC, assimilate, Assimilation, ASU, Augusta, Avid, Baker, Barnett, Bipartisan, BIVIP, BIVIVP, bolster, BPCI, broiler, chicken, Christensen, compatible, compliant, conspiracy, contest, corrective, CureVac, curtailment, Daniel, deploy, disproportionate, Dodge, Dual, Eagle, error, exploitation, exploring, Florida, Fort, founder, fraud, fundamentally, Galliprant, gather, Georgia, GILTI, hardware, hookworm, Hurricane, installment, interference, Iowa, Johna, Joshua, KeyBioscience, lanabecestat, Ltda, merger, metabolic, Microsoft, middle, Minnesota, Mississippi, misused, MSP, narrative, Nektar, Nipro, Norton, obsolescence, owed, PCAOB, pertinent, Pharm, plaintiff, provisional, Pusey, Quimica, Rabvac, Radiopharmaceutical, rbST, reclassification, refile, regime, remeasurement, remeasuring, rendered, Restated, Resubmitted, retention, retroactive, RNActive, roundworm, rulemaking, scheme, Shah, Shaw, shut, Skovronsky, Smiley, Stada, Strafford, stranded, Streck, succeeded, superseded, surfaced, tapeworm, temporarily, Toll, unsealed, Verzenio, VerzenioTM, Washington, whipworm, withholding, XR
Removed:
Abbott, absence, Allergan, amendment, API, applicator, apportioned, attention, awarded, Barton, bound, chairman, choose, close, Crowe, Cuxhaven, Derica, evacetrapib, extra, FASB, finance, Fionnuala, granting, headquartered, Immunocore, indemnify, issue, Ixekizumab, John, leader, Lechleiter, lodged, Lohmann, Louisiana, Necitumumab, neutralizing, operational, opposition, PCI, peglispro, Peterson, ratio, remained, remitted, repaid, repatriated, Rice, Saavedra, Sandoz, SE, Shionogi, subsequently, supporting, taxed, topical, underarm, variability, Walsh
Filing tables
Filing exhibits
- 10-K Annual report
- 10.2 Eli Lilly and Company Performance Award (for Executive Officers)
- 10.3 Exhibit 10.3
- 12 Statement Re: Computation of Ratio of Earnings (Loss) to Fixed Charges
- 21 List of Subsidiaries and Affiliates
- 23 Consent of Independent Registered Public Accounting Firm
- 31.1 Rule 13A-14(A) Certification of David A. Ricks, President & Chief Executive Offi
- 31.2 Rule 13A-14(A) Certification of Derica W. Rice, Executive Vice President, Global
- 32 Section 1350 Certification
- Download Excel data file
- View Excel data file
Related press release
Associated LLY transcripts
LLY similar filings
Filing view
External links
EXHIBIT 12. Statement Re: Computation of Ratio of Earnings to Fixed Charges
ELI LILLY AND COMPANY AND SUBSIDIARIES
Years Ended December 31, | ||||||||||||||||||||
2017 | 2016 | 2015 | 2014 | 2013 | ||||||||||||||||
(Dollars in millions) | ||||||||||||||||||||
Consolidated pretax income | $ | 2,197.4 | $ | 3,374.0 | $ | 2,790.0 | $ | 3,000.3 | $ | 5,889.3 | ||||||||||
Interest(1) | 282.3 | 232.9 | 216.0 | 187.1 | 184.2 | |||||||||||||||
Less interest capitalized during the period | (57.3 | ) | (47.7 | ) | (54.8 | ) | (38.3 | ) | (24.1 | ) | ||||||||||
Earnings | $ | 2,422.4 | $ | 3,559.2 | $ | 2,951.2 | $ | 3,149.1 | $ | 6,049.4 | ||||||||||
Fixed charges | $ | 282.3 | $ | 232.9 | $ | 216.0 | $ | 187.1 | $ | 184.2 | ||||||||||
Ratio of earnings to fixed charges | 8.6 | 15.3 | 13.7 | 16.8 | 32.8 |
(1) Interest is based upon interest expense reported as such in the consolidated statements of operations and does not include any interest related to unrecognized tax benefits, which is included in income tax expense.